Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling.
Cancer Lett
; 319(1): 98-108, 2012 Jun 01.
Article
en En
| MEDLINE
| ID: mdl-22265862
ABSTRACT
Sorafenib is a multi-kinase inhibitor applicable to hepatocellular carcinoma (HCC), but its limited therapeutic effects are a major problem to be solved. Here, we show that blockade of ataxia telangiectasia mutated (ATM) improves the antitumor effects of sorafenib. When hepatoma cell lines HepG2 and PLC/PRF/5 were treated with sorafenib plus ATM small inhibitory RNAs, ATM inhibitor KU55933 or caffeine, Akt signaling was suppressed and the cytotoxic effects were significantly potentiated. Moreover, ATM inhibition effectively suppressed the sorafenib-induced cell migration. Taken together, manipulation of ATM activity might be a useful strategy for improving sorafenib treatment of HCC.
Texto completo:
1
Bases de datos:
MEDLINE
Métodos Terapéuticos y Terapias MTCI:
Terapias_biologicas
/
Aromoterapia
Asunto principal:
Piridinas
/
Bencenosulfonatos
/
Proteínas Serina-Treonina Quinasas
/
Carcinoma Hepatocelular
/
Proteínas de Ciclo Celular
/
Proteínas Supresoras de Tumor
/
Proteínas de Unión al ADN
/
Neoplasias Hepáticas
/
Antineoplásicos
Idioma:
En
Revista:
Cancer Lett
Año:
2012
Tipo del documento:
Article
País de afiliación:
Japón